onartuzumab   Click here for help

GtoPdb Ligand ID: 8966

Synonyms: MetMAb | OA-5D5 | OA5D5 | PRO 143966
Compound class: Antibody
Comment: Onartuzumab is an investigational, humanized monoclonal antibody targeting the MET receptor tyrosine kinase, a proto-oncogene which acts as a hepatocyte growth factor receptor. The protein is a monovalent (single-armed) construct, as opposed to bi-valent intact antibody structures.
Peptide sequence information for this antibody is available from its IMGT/mAb-DB record.
BLAST peptide analysis reveals identical match with sequences deposited with patent US7615529 [4], which relate to the monoclonal isolated from hybridoma 5D5.11.6 therein.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
References
1. Charakidis M, Boyer M. (2014)
Targeting MET and EGFR in NSCLC-what can we learn from the recently reported phase III trial of onartuzumab in combination with erlotinib in advanced non-small cell lung cancer?.
Transl Lung Cancer Res, 3 (6): 395-6. [PMID:25806331]
2. Huang A, Schwall R, Yansura D. (2005)
Monovalent antibody fragments useful as therapeutics.
Patent number: US20050227324 A1. Assignee: Genentech, Inc.. Priority date: 19/12/2003. Publication date: 13/10/2005.
3. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, Zbar B, Vande Woude GF. (1997)
Activating mutations for the met tyrosine kinase receptor in human cancer.
Proc Natl Acad Sci USA, 94 (21): 11445-50. [PMID:9326629]
4. Kong-Beltran M, Wickramasinghe DM. (2009)
Methods and compositions for modulating hyperstabilized c-met.
Patent number: US7615529 B2. Assignee: Genentech, Inc.. Priority date: 05/01/2016. Publication date: 10/11/2009.
5. Meiners S, Brinkmann V, Naundorf H, Birchmeier W. (1998)
Role of morphogenetic factors in metastasis of mammary carcinoma cells.
Oncogene, 16 (1): 9-20. [PMID:9467938]
6. Morley R, Cardenas A, Hawkins P, Suzuki Y, Paton V, Phan SC, Merchant M, Hsu J, Yu W, Xia Q et al.. (2015)
Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program.
PLoS ONE, 10 (10): e0139679. [PMID:26445503]
7. Rolfo C, Van Der Steen N, Pauwels P, Cappuzzo F. (2015)
Onartuzumab in lung cancer: the fall of Icarus?.
Expert Rev Anticancer Ther, 15 (5): 487-9. [PMID:25818471]